AXGT

Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicinesCompany’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, today announced it will change its name to Sio Gene Therapies, Inc., effective November 13, 2020. In connection with the name change, the company’s ticker will change to “SIOX” and will be effective at market open on November 13, 2020, along with th

AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseasesRepresents Axovant’s second IND clearance for a gene therapy program in the last 12 months NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has lifted its clinical hold and cleared the Investigational New Drug (IND) Application to initiate a registrational study of AXO-AAV-GM2 gene therapy to treat patients with Tay-Sachs disease and Sandhoff disease. AXO-AAV-GM2 is the first investigational gene therapy to achiev

Patient-level data in cohort 2 of SUNRISE-PD study demonstrates consistent, clinically meaningful outcomes and evidence of dose responseDelays in manufacturing process expected to postpone the start of enrollment in randomized, controlled studyVirtual R&D Day webcast on October 30th at 11:30 AM Eastern time NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced program updates to be presented as part of its virtual R&D Day on Friday, October 30, 2020 at 11:30 AM Eastern time, for the Company’s AXO-Lenti-PD gene therapy for Parkinson’s disease. Axovant’s Parkinson’s disease R&D

PALM BEACH, FL, Oct. 27, 2020 /PRNewswire/ -- Every year, the number of cancer-related deaths caused due to gastric cancer has been reaching to more than 800,000, as per the records of the World Health Organization. In the recent past, the number of people diagnosed with gastric cancer was approximately in thousands, according to the American Cancer Society. Thus, growing incidence of gastric cancer across the world is foreseen to push the global market for the next few years. Age, diet, and stomach disease can affect the risk of developing stomach cancer. Symptoms of stomach cancer include indigestion and stomach discomfort or pain. This type of cancer is difficult to diagnose because mo

Agenda to feature presentations from leading clinical researchers in Parkinson’s disease and the Michael J. Fox FoundationIndividual patient-level data from Cohort 2 of the Phase 2 SUNRISE-PD study to be shared NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host a virtual R&D Day on Friday, October 30, 2020 at 11:30 AM Eastern time, to discuss the Company’s AXO-Lenti-PD gene therapy for Parkinson’s disease. Axovant’s Parkinson’s disease R&D Day will be moderated by Chief R&D Officer, Gavin Corcoran, M.D., and will feature presentations on th

NEW YORK, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for AXO-AAV-GM1, an AAV9-based gene therapy delivered via a single intravenous administration that is in Phase 1/2 development for GM1 gangliosidosis. In addition to the Rare Pediatric Disease designation, AXO-AAV-GM1 has Orphan Drug designation and is the only gene therapy in clinical development for both infantile (Type I) and juvenile (Type II) GM1 gangliosidosis. “Receiving Rare Pediatric Dis

Kristiina Vuori, M.D., Ph.D. is a leading genetics and cancer researcher who serves as President and Board member of Sanford Burnham Prebys Medical Discovery InstituteAppointment of Dr. Vuori establishes a majority independent Board of DirectorsParag V. Meswani, Pharm.D., promoted to Chief Commercial Officer to support Axovant’s commercialization efforts across clinical-stage pipeline NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced the appointment of Kristiina Vuori, M.D., Ph.D., to its Board of Directors and the promotion of Parag. V. Meswani, P

• AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months• 21-point mean improvement in UPDRS Part III “OFF” score, a 40% improvement from baseline, exceeding pre-defined criteria for success• Greater than 2-hour improvement from baseline in both diary “good ON time” and diary OFF time assessments• EXPLORE-PD, a randomized, sham-controlled study of AXO-Lenti-PD is expected to begin dosing in 2021 NEW YORK, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, today reported six-month follow-up data from the second cohort of

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will present at upcoming conferences and will announce six-month safety and efficacy data from the second cohort of its AXO-Lenti-PD program the morning of Tuesday, October 6, 2020. Additionally, as previously announced the Company will hold a Parkinson’s Disease R&D Day on Friday, October 30. Information on the upcoming presentations can be found below: Chardan 4th Annual Genetic Medicines Conference Date:Tuesday, October 6, 2020Time:2:30 PM ETParticipation Format:Fireside chat with Gbola Amusa, MD, CFA